Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1650002
Max Phase: Preclinical
Molecular Formula: C17H16N6O3
Molecular Weight: 352.35
Molecule Type: Small molecule
Associated Items:
ID: ALA1650002
Max Phase: Preclinical
Molecular Formula: C17H16N6O3
Molecular Weight: 352.35
Molecule Type: Small molecule
Associated Items:
Synonyms (1): DB1679
Synonyms from Alternative Forms(1):
Canonical SMILES: CO/N=C(/N)c1ccc(-c2ccc(-c3ccc(/C(N)=N/O)cn3)o2)nc1
Standard InChI: InChI=1S/C17H16N6O3/c1-25-23-17(19)11-3-5-13(21-9-11)15-7-6-14(26-15)12-4-2-10(8-20-12)16(18)22-24/h2-9,24H,1H3,(H2,18,22)(H2,19,23)
Standard InChI Key: RTNOOAOQALMKNE-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 352.35 | Molecular Weight (Monoisotopic): 352.1284 | AlogP: 1.76 | #Rotatable Bonds: 5 |
Polar Surface Area: 145.14 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 11.30 | CX Basic pKa: 5.01 | CX LogP: 0.80 | CX LogD: 0.80 |
Aromatic Rings: 3 | Heavy Atoms: 26 | QED Weighted: 0.27 | Np Likeness Score: -0.69 |
1. Wenzler T, Boykin DW, Ismail MA, Hall JE, Tidwell RR, Brun R.. (2009) New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289., 53 (10): [PMID:19620327] [10.1128/aac.00225-09] |
2. Generaux CN, Ainslie GR, Bridges AS, Ismail MA, Boykin DW, Tidwell RR, Thakker DR, Paine MF.. (2013) Compartmental and enzyme kinetic modeling to elucidate the biotransformation pathway of a centrally acting antitrypanosomal prodrug., 41 (2): [PMID:23223498] [10.1124/dmd.112.048231] |
Source(1):